Announces data from two phase 3 Bimekizumab studies in psoriatic arthritis to be presented at EULAR 2022
- First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively
- A higher proportion of patients treated with bimekizumab vs. placebo achieved improvements in joint symptoms at week 16 as measured by ACR50, with a consistent clinical response across biologic-naïve (43.9% vs. 10.0%; p<0.001) and TNF-inadequate responder populations (43.4% vs. 6.8%; p<0.001)
- At week 16, a greater proportion of bimekizumab-treated patients achieved high levels of skin clearance, PASI90, vs. placebo, with a consistent clinical response across populations (61.3% vs. 2.9% for biologic naïve and 68.8% vs. 6.8% for TNF-inadequate responders; p<0.001 for each)
- At week 16, over 40% of bimekizumab-treated patients vs. placebo achieved minimal disease activity in both studies (p<0.001)
- The results will be presented at the European Congress of Rheumatology, EULAR 2022, in Copenhagen June 1st - June 4th.